A. M. Belousov-iub, [Biological resonance as a possible mecha..11ism of an ototoxic action of aminoglycoside antibiotics

A. M. Ulcamy-f and M. C. , Pharmacokinetics and potential interaction among antiretroviral agents used to treat patient with HIV, Clin. Pharmacokinenet, vol.36, pp.289-304, 1999.

B. J. Kivisto-k, . T. Olkkola-k, and . J. Neuvonen-p, The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampin. Eur, J. Clin. Pharmaco.l, vol.54, pp.53-58, 1998.

B. J. Kyrklund-c and . Neuvomen-m, Gemfibrozil greathly increases plasma concentration of cerivastatin, Clin. Pharmacol. Ther, vol.72, pp.685-691, 2002.

B. T. Basin-k, . Escalante-a, and . Beardmore-t, Comment traiter un goutteux résistant ou allergique à l'allopurinol en, Severe pancytopenia in a patient taking low dose methorexate and probenecid, pp.860-864, 2004.

B. G. , Z. F. Horsmans-y, and . Lambert-m, Potentialisation fe l'effet anticoagulant de l'acénocoumarol par un gel oral de miconazole, pp.177-178, 1998.

B. Youmeu, F. , A. M. , K. A. Steschenko-g, and L. M. , Angor et sulprostone au cours d'une hémorragie de la délivrance Ann, Fr. Anesth. Réanim, vol.21, pp.668-671, 2002.

B. C. Bentue-ferrer-d, R. J. Bes, . Hardy-g, and . Chartier-a, Les interactions médicamenteuses Angeiologie Polymorphisme génétique et traitement des maladies inflammatoires chroniques de l'intestin: exemple de l'azathioprine Thérapie, pp.67-77, 1997.

B. L. , L. M. Bousquet-p, . Gayet-j-], . A. Branch-r, . Adedoyin-a et al., La pharmacogénétique: application aux anticoagulants oraux Sang Thrombose Vaisseaux Caractéristiques pharmacologiques de la rovustatine, un nouvel antagoniste de l'HMGCoA reductase, vivo modulation of CYP enzymes by quinidine and rifampin, pp.357-633, 2000.

B. E. , W. D. , M. B. Chan-a, . T. Liu-d, G. I. Friedman-d et al., Ototoxic drugs. I. Aminoglycoside antibiotics] Wiad Doxycycline and intracranial hypertension Gentamicin induced apoptosis of renal tubular epithelial (LLC-PKl) cells. Korean Identification of drugs inhibiting the in vitro metabolism oftacrolimus by human liver microsomes. Br, Neurology. J Infern. Med. J Clin. Pharmacol, vol.5620, issue.41, pp.254-259, 1996.

C. M. Desmeules-p, K. R. Da-yer-p-]-connell-w, and R. J. Lennard-jones, La glycoprotéine P : un transporteur de médicaments à ne pas négliger Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of expenence, Med. Hyg. Gut, vol.6223, issue.34, pp.704-709, 1993.

C. E. Mrozek-e and P. S. , Delayed development of pulmonary toxicity syndrome following busulfan preparative therapy for allogeneic marrow transplantation, Blood, vol.96, pp.346-371, 2000.

C. D. Sekar-m, . Halil-o, and . Banner-n, Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation, Transplantation, vol.61, pp.1661-1662, 1996.

D. S. Holm-g and . Svanborg-n, Clinical and morphological side effects of Busulfan (Myrelan) treatment

. Acta, . Med, D. C. Scand-de, . Queinnec-m, . Pinaud-m et al., Interactions avec les nouveaux macrolides, Journal de Pharmacie Clinique, vol.19227, issue.16, pp.129-135, 1972.

D. J. , J. A. , N. D. Geffroy-c, and C. C. , Preventable and non-preventable risk factors for adverses drug events related to hospital admissions in the elderly. A prospective study, Clin. Drug Invest, vol.22, pp.385-392, 2002.

D. J. and C. P. Trivallec, Drug-drug interactions related to hospitals admissions in older adults: a prospective study of 1 000 patients

D. G. , S. J. Bailley-d, . D. Dun, . Stieger-b, and . A. Kullak-ubdlich-g, Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P-450 3A4 inhibition St John's wort extract induces intestinal p glycoproteine /MDRl and intestinal and hepatic cytochrome CYP 3A4 in manCoordinate induction ofboth cytochrome P450 3A and MDR 1 by St John's wort in healthy subjects Clin, Clin Pharmacokinet Clin. Pharmacol. Ther. Pharmacol. Ther, vol.383334, issue.731, pp.41-57, 2000.

E. M. Rees-a-]-fleishaker, R. K. , and J. J. , Effects ofHMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug., Saf, pp.649-663, 2002.

F. F. Fraunfelder-f and C. J. , Isotretinoinassociated intracranial hypertension [40] FRIEDMAN D.I. Medication-induced intracranial hypertension in dermatology, Ophthalmology Am. J. Clin. Dermatol, vol.111, issue.6, pp.1248-1250, 2004.

F. D. and G. L. Egan-r, Doxycycline and intracranial hypertension Discordances d'informations sur les interactions médicamenteuses: analyse par un auteur d'une base de données informatisée sur le médicament pour les professionnels de santé, Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity, pp.2297-2299, 2004.

G. J. Hamman-m, W. Z. , V. Asa-v-adan, . S. Huang, and . S. Hall, The effect of StJohn' s wort on the efficacy of oral contraception

S. John-'s-wort, I. J. Pouyane-p, and . Haramburu-f, drug interactions and clinical outcomes Br Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français, J. Clin. Pharmacol. Thérapie, vol.5447, issue.54, pp.349-56, 1999.

L. I. Kajosaari, . T. Backman-j, L. J. Neuvonen-m, and . J. Neuvonen-p, Pharmacokinetic interaction of digoxine with an herba! extract from St John's wortLack of effect ofbezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamies of repaglinide, Clin. Pharmacol. Ther. Br. J. Clin. Pharmacol, vol.6650, issue.58, pp.358-403, 1999.

K. L. , L. J. Neuvonen-p, and B. J. , Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin, Basic. Clin. Pharmacol. Toxicol, vol.97, pp.249-256, 2005.

K. N. , K. P. , E. P. Chapman-r, A. N. , G. Fuhr-u et al., Oesophagal varices associated with busulphan-tioguanine combination therapy for chronic myeloid leikemia Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP 1A2 Clin, Lancet Pharmacol. Ther, vol.253, issue.65, pp.1050-1052, 1987.

K. A. Wagner-b and . Moritz-e, Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline

T. M. Sad-err, . Gauthier-m, L. A. Basin-b-], and . Maddix-d, Emploi simultané des calcibloqueurs et du dandrolène dans le syndrome malin des neuroleptiques, Réan. Soins Intens. Méd. Urg, vol.5160, issue.2, pp.177-184, 1986.

L. F. Megerlin-h, Projet d'insertion de l'Opinion Pharmaceutique et du dossier de suivi pharmaco-thérapeutique dans les logiciels existant à l'officine

L. D. Wisniewski-s, Rifampicine et P-glycoprotéine: un nouveau mécanisme d'interaction pharmacocinétique

A. Lo, . J. Burckart-g, C. C. Marotel, R. B. Vasseur-p, and C. J. , P-glycoprotein and Drug Therapy in Organ Transplantation, The Journal of Clinical Pharmacology, vol.18, issue.10, pp.995-1005, 1999.
DOI : 10.1177/00912709922011755

M. G. Baud-p, Crise migraineuse: que savons-nous vraiment des triptans? Neurologies, pp.468-472, 2002.

M. and S. S. Lown-k, Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans, Clin. Pharmaco.l Ther, vol.72, pp.1-9, 2002.

N. Y. Ikeda-s and W. T. Furuka, Cellular localization of the multidrugresistance gene product P glycoprotein in normal tissues, Proc. Nat./ Acad Sei, pp.7735-7738, 1987.

N. A. Snheider-b, . K. Baker-r, . J. Kroll-d, . Niemi-m, . T. Backman-j et al., Potential metabolic interaction between St John's and théophylline Ann. Pharmacother Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamies of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide, Diabetologia, vol.33, issue.46, pp.502-77, 1999.

N. Blet-c, « French national post marketing surveillance of sildénafil: a five year experience study »: 9ème congrès annuel de la société française de pharmacologie, Fundamental. Clin. Pharmacol, vol.19, p.203, 2005.

O. P. Dugue, . Montastruc, and . Jl, Effets indésirables cardiovasculaires et neurologiques centraux des sympathomimétiques utilisés comme décongestionnants de la sphère ORL: analyse de la Banque Nationale de pharmacovigilance, Miconazole oral get enhances acenocoumarol anticoagulant activity : A report of three cases, pp.361-366, 2003.

J. Pharm-clin-]-perit-!-p, . Mazzei-t, . Mini-e, and . Novelli-a, Pharmacokinetic drug interactions of macro li des, Clin. Pharmacokinet, vol.1682, issue.23, pp.75-81, 1992.

P. P. Haramburu-f and I. J. Begaud-b, Admissions to hospitals caused by adverse drug reactions: cross sectionnai incidence study, BMJ, vol.320, pp.1036-1037, 2000.

P. S. Burstein-a and C. D. , Indinavir concentration and StJohn's Wort, Lancet, vol.355, issue.923, pp.547-548, 2000.

R. Prescrire-]-redaction-prescrire-], R. R. , and G. D. Kunze-k, Interactions médicamenteuses : comprendre et décider Coxibs +anticoagulants oraux: gare aux interactions Rev Mecanisms of the stereoselective interaction between miconazole and racemic warfarin in human subject, Rev. Prescr. Prescr. Clin. Pharmacol. Ther, vol.27087, issue.51, pp.26-27, 1992.

. Gac, . Med, R. A. Mex, Z. A. Hyperkaliema, R. F. et al., Acute heart transplantation rejection duet o St John's wort Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery, Effect of oral pseudoephedrine on blood pressure and heart rate, pp.705-711, 1987.

S. L. , K. R. , C. B. , N. E. Heath-k-], J. A. San et al., Hyperkaliemia and cardiovascular collapse after verapamil and dantrolene administation in swine Hyperkalemia after dantrolene and verapamil-dantrolene administration in dogs al. The effect of gemfibrozil on the pharmacokinetics of rovustatin, Anesh. Analg. Anesth. Analg. Clin. Pharmacol. Ther, vol.63, issue.75, pp.473-478, 1984.

S. M. , G. A. Tincani-e, and . Iorio-a, Miconazole oral gel potentiates warfarin anticoagulant activity, Thromb. Haemost, vol.83, pp.794-795, 2000.

S. C. Drolet-b, Le syndrome du QT long médicamenteux. Québec Pharmacie, pp.381-385, 2003.

T. J. Hreiche-r, Interactions médicamenteuses et risque de torsades de pointes. Pharmactuel, pp.134-139, 2005.

U. Aj, Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole, Curr. Med Res. Opin, vol.19, pp.263-71, 2003.

V. B. Coulson-a, . S. Bernstein-g, and . M. Nakamura-r, Minerai oil lubricants cause rapid deterioration of latex condoms, Contraception, vol.39, pp.95-102, 1989.

W. J. Neuvomen-m and W. X. , Gemfibrozil inhibits CYP 2C8- mediated cerivastatin metabolism in human liver microsomes, Drug. Metab. Dispos, vol.30, pp.1352-1356, 2002.

W. D. , F. S. , and A. M. Muirhead-g, Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist

W. D. Muirhead-g and . Wulff-m, Sildenafil citrate potentiates the hypotensive effects of ni tric oxide donor drugs in male patients with stable angina, J. Am. Coll. Cardial, vol.36, pp.25-31129, 2000.

A. Carter, Wallace debuts new polyurethane condom in U, S. Contracept. Technol. Update, vol.20, pp.73-75, 1999.

C. Central and D. Pharmaciens-d-'officine-«-l, Opinion Pharmaceutique» In : CONSEIL CENTRAL DES PHARMACIEN D'OFFICINE Guide de stage de fn,ratique professionnelle en officine : pharmacie générale officine, 6ème année. -13 me édition, pp.64-71

C. Pfizer and . Inc, Monographie du VIAGRA Date de révision : 05 février 2004 [123] PFIZER Mention légales RELP AX® Date de révision, p.5

A. Nationale and D. Pharmacie, Interaction médicamenteuse, In: dictionnaire des sciences pharmaceutiques et biologique 2ème édition, pp.836-837, 2001.

B. S. Ohman-l, Antidepressant drugs. In DUKES MNG EDITOR. Meyler 's side effects of drugs, pp.33-85, 2000.

C. J. Brudieu-e, . F. Allenet-b-gimenez, C. J. Brazier-m, and . Dine-t, Méthodologie de validation d'ordonnance, pp.29-34, 2002.

F. P. Fernandez-c-gimenez, C. J. Brazier-m, and . Dine-t, «Prévention de l'iatropathologie liée à la chimiothérapie anticancéreuse, Pharmacie clinique et thérapeutique-2e édition, pp.635-661, 2002.

A. S. Garwala, . Eley-t, and . Villegas-c, Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. [ Abstract 11.] Pro gram and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy, 2005.

S. M. and F. S. Wire-m, Coadministration of esomeprazole (ESO) with fosamprenavir (FPV) has no impact on steady-state plasma amprenavir (APV) pharmacokinetics (APVl 0031 ). [ Abstract 24] Pro gram and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy, Thésaurus des interactions médicamenteuses, 2005.

. Haute, . De, and . Fches, medicaments anti-infectieux en pathologies communautaires http, 2004.

H. S. Reyataz, M. De, L. Sante, L. De, M. Solidarite-web-site-«-l-'iatrogénie-médicamenteuse-en-france et al., Dear Health Care Provider Letter Syndrome sérotoninergique et intoxication par les antidépresseurs inhibiteurs de la recapture de la sérotonine (ISRS) et les inhibiteurs de la monoamine oxydase (IMAO).Mars, ISRS.pdf [156] PAINTAUD G. «Systèmes adrénergiques et cholinergique» Mises à, 2000.

/. Bret-agne-/-santebretagne and /. , pdf [160] THERIAQUE site web Base de données sur les médicaments du CNHIM, France, pour les professionnels de la santé. www.theriaque.org [161] URCAM Alsace web site Associations médicamenteuses formellement contre-indiquées Actions de prévention du risque iatrogène. http://www.alsace.assurance-maladie.fr/uploads/media/afci.pdf [162] URCAM Auvergne Les associations médicamenteuses formellement contre-indiquées http://www. urcam.assurancemaladie .fr/fileadmin/ AUVERGNE/publications/ AFCI.pdf [163] URCAM Bretagne Les interactions médicamenteuses à risque vital en Bretagne httpfileadmin/LIMOUSIN/publications/synth intermed 0602.pdf [165] URCAM Nord Pas-de-Calais web site Les interactions médicamenteuses. Contre-indication absolue dans le Nord Pas-de Calais. Mars, Lettre de Pfizer Canada Inc du 28PD F /Synthese 2 7 .pdf [164] URCAM Limousin web site Interactions médicamenteusespdf [166] URCAM Poitou-Charentes web site « Etude prospective des admissions de personnes âgées pour iatrogénie médicamenteuse en Poitou Charentes167] URCAM Rhône-Alpes. Web site Les associations médicamenteuses formellement contre indiquées http, 2000.

. Urcam-rhône-alpes, Web site Programme régional de l'assurance maladiePRAM) http://www.rhone-alpes.assurance-maladie.fr/fileadmin/RHONE- ALPES/publications/PRAM, 2004.

. Arreté-du-11juillet2006, portant approbation à la convention nationale organisant les rapports entre les pharmaciens d'officine et l 'Assurance Maladie, 2006.

!. ·lip:-u-!-tu and . U-gapn-9-'jq, tJli!.tUUUJ ra 9'.tttanm 9'aJ a.tifutn.t.tUl .tttf!rl rnr~ unm ra ga1ungg1nuun1 liam .tarrnnn ~ !n.tnua9'un1 · au aî gn1 un1nn ua ! au1nmn4 ~nuff!'Q. n li ra a q_n1nm a1 9'.tanua !;r.t1nnaq_ liam ia ~nnqnliunrllia